🧾 What This Document Is

This is an 8-K filing with an exhibit attached. The 8-K itself is a current report announcing a major event. The attached Exhibit 2.1 is the actual, legally-binding "Agreement and Plan of Merger" between Biogen, a subsidiary called Aspen Purchaser Sub, and Apellis Pharmaceuticals. It's the detailed rulebook for how Biogen plans to buy Apellis. 👉 In simple terms: This is the signed contract for Biogen's acquisition of Apellis.

🏢 What The Companies Do

Biogen Inc. (BIIB): A major global biotechnology company focused on neuroscience (like treatments for Alzheimer's, MS) and now expanding into other areas like immunology.
Apellis Pharmaceuticals, Inc.: A smaller biopharma company focused on developing therapies for complement-mediated diseases, with a key drug in areas like geography atrophy (an eye disease). 👉 Why they're pairing up: This deal allows Biogen to add Apellis's promising drugs and pipeline to its own portfolio, strategically expanding its business beyond neuroscience.

💰 The Deal Price & Structure

This isn't a simple all-cash offer. The payment to Apellis shareholders has two parts:

$41.00 per share in cash. This is the guaranteed, immediate payment.
One Contingent Value Right (CVR) per share. This is a special "IOU" that could pay additional cash in the future if Apellis's drugs hit specific sales milestones.

👉 The maximum potential payout is $45.00 per share ($41 cash + up to $4 from the CVRs). The CVRs could be worth $0 if sales targets aren't met. This structure lets Biogen share risk and reward with Apellis shareholders based on future success.

🚀 How The Deal Works: Tender & Merger

The purchase happens in two main steps, designed for speed:

Step 1: The Cash Tender Offer. Biogen's subsidiary (Aspen Purchaser) will launch a formal offer to buy all of Apellis's shares at the offer price. Shareholders can choose to "tender" (sell) their shares directly into this offer.
Step 2: The "Short-Form" Merger. Once Biogen buys enough shares via the tender offer (over 50%), they will immediately merge the subsidiary into Apellis. Any shares not sold in the tender are automatically converted into the right to receive the same $41 + CVR deal. No separate shareholder vote is required thanks to a Delaware law shortcut.

👉 Why it matters: This two-step process is standard for friendly takeovers. It's faster than a traditional merger requiring a full shareholder vote, getting cash to selling shareholders sooner.

📦 The Contingent Value Rights (CVRs) Explained

The CVRs are a key, complex part of the deal. They trade separately from the stock and can pay out if Apellis's lead drug, Empaveli (used for PNH and c3g diseases), hits annual net sales targets:

Milestone 1: If Empaveli achieves $1.3 billion in annual net sales by any year from 2027-2031, CVR holders get $2.00 per CVR.
Milestone 2: If Empaveli achieves $2.3 billion in annual net sales by any year from 2027-2031, CVR holders get an additional $2.00 per CVR.
Deadline: Payments stop after January 31, 2032, or once milestones are paid, whichever is earlier.
Governance: A group of major CVR holders ("Acting Holders") can audit sales figures and dispute calculations.

👉 What this signals: Biogen is confident in the drug's potential but is aligning final payment with proven commercial success. It's a "bet on the future" for Apellis shareholders.

⚖️ Legal & Governance Details

Approval: Apellis's Board of Directors has unanimously recommended that shareholders tender their shares, calling the deal "fair."
Breakup Fee: If Apellis accepts a better offer from someone else, it must pay Biogen a fee of $155 million.
Shop Limit: Apellis is restricted from actively seeking other buyers (a "no-shop" clause).
Employees: Key Apellis employees have signed "Tender and Support Agreements," agreeing to sell their shares to Biogen.

🔮 What Happens Next & Risks

Next Steps: The tender offer will start within 10 business days of this agreement (early April 2026). It will last at least 20 business days. If successful, the merger could close by mid-2026.

Key Strengths (👍):

Offers a premium price to Apellis shareholders.
Provides immediate cash ($41) plus a potential bonus ($4).
Structured for a swift, efficient closing.

Key Risks (⚠️):

Regulatory Hurdle: The deal requires clearance from antitrust regulators. Any delay or challenge could jeopardize it.
Deal Conditions: The offer can be called off if certain conditions aren't met, including Apellis's business not suffering a major negative change before closing.
CVR Uncertainty: The extra $4 per share is not guaranteed—it depends entirely on future drug sales that are hard to predict.

🧠 The Analogy

Think of this like buying a special edition comic book. The upfront cash payment of $41 is like paying the sticker price for the book itself. The CVR is like a sealed "mystery variant cover" that comes with it. That variant cover could be worthless, or it could become very valuable if the character's popularity soars in future movies (i.e., if the drug's sales hit big). You're paying a set price now but get a lottery ticket for future success built into the deal.

📇 Key Contacts & People

Biogen Inc. (Parent)
Aspen Purchaser Sub, Inc. (Purchaser, wholly owned sub of Biogen)
Apellis Pharmaceuticals, Inc. (Company)
Rights Agent: To be mutually agreed upon by Biogen and Apellis (will administer the CVRs).
Paying Agent: Equiniti Trust Company, LLC (or another approved bank) will handle the cash payments.

🧩 Final Takeaway

Biogen is acquiring Apellis for a base price of $41 per share in cash, plus a potential extra $4 per share based on future drug sales performance. The deal is structured for a quick close via a tender offer and merger, backed by Apellis's board recommendation. It's a strategic move for Biogen to grow its drug portfolio, with the final price tag partly tied to how well Apellis's key product performs in the market.

BIOGEN INC. — 8-K Filing